Anthony Bekasiak, MD
Critical Care Medicine · Lewiston, MENPI 1639699416
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (37.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Intuitive Surgical at 57.2% of the total. 2025 is the largest year on record at $4,280, 4.3 times the $1,000 reported in 2020.
Across 95 payments — averaging $73.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Merck$1K
- AstraZeneca$511
- Mallinckrodt Hospital Products Inc.$286
- GSK$251
- Philips North America LLC$208
- plus $735 from 12 others
What the payments were for
- Grants$1,00014%
- Travel & lodging$1,48221%
- Food & beverage$1,91127%
- Education$2,60037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $4,002 |
| Merck | 1 | $1,000 |
| AstraZeneca | 19 | $511 |
| Mallinckrodt Hospital Products Inc. | 8 | $286 |
| GSK | 16 | $251 |
| Philips North America LLC | 8 | $208 |
| United Therapeutics Corporation | 5 | $121 |
| Sanofi | 5 | $112 |
| Electromed, Inc. | 5 | $99 |
| Jazz Pharmaceuticals Inc. | 2 | $67 |
| Mylan Specialty L.p. | 2 | $64 |
| Boehringer Ingelheim | 2 | $55 |
| Verona Pharma, Inc. | 2 | $51 |
| Novartis | 2 | $46 |
| Amgen | 2 | $44 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,848
- FASENRA$117
How this compares
Too few critical care medicine providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 190 | $219,164 |
| Dupixent SyringeDupilumab | 14 | $49,878 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $39,671 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $35,823 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $26,882 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $19,626 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $15,072 |
| Serevent DiskusSalmeterol Xinafoate | 19 | $12,224 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $8,334 |
| Pirfenidone | 11 | $7,553 |
| Roflumilast | 41 | $7,381 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 149 | $6,447 |
| DuleraMometasone/Formoterol | 13 | $5,345 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,594 |
| Varenicline Tartrate | 12 | $2,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $251 | $300,789289 claims |
| Boehringer IngelheimStiolto Respimat | $55 | $35,82337 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $511 | $27,96032 claims |
| MerckDulera | $1,000 | $5,34513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in Maineon file to place this against a meaningful peer group, so we don't.
Other critical care medicine in Lewiston
- Christopher CookLewiston$125
- Rafael Jose GrozmanBangor$2K
- Jacob PaulBangor$684
- Danielle PoulinPortland$521
- Megan RushmeyerPortland$250
- Bryant ShannonPortland$245
- Faryal MalickBangor$202
- Colman HattonSouth Portland$110
- Crystal AdamsYork$100
- Matthew CravensPortland$53
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.